All News
Effect of Intraarticular Steroid Shots on Knee OA Outcomes
d
MedPage Today
In patients with osteoarthritis (OA) of the knee, intra-articular injections of steroids did not increase rates of either disease progression or subsequent knee replacement surgery, researchers said.
Read Article
Are Shoulder Conditions Incited by Vaccination?
A retrospective cohort study from Kaiser Permanente Southern California intramuscular vaccination given between 2016 and 2017 shows a small but significant increase in shoulder conditions, reported as an adverse event (AE) following intramuscular vaccination in the deltoid muscle.
Read Article
Adalimumab Addition vs. Methotrexate Escalation in Psoriatic Arthritis
An interesting study in Lancet Rheumatology shows that psoriatic arthritis patients not responding to methotrexate alone can respond after adding or escalating adalimumab (ADA) on top of methotrexate (MTX) to reach minimal disease activity (MDA) response.
Read Article
Swedish study found 1774 systemic sclerosis (SSc) pts in 2015 w/ median age 65 yrs (84% women) = prevalence=22.7 per 100,000 . Incidence (2004-2015) was 11.9 per 1,000,000 PYs - incidence remained stable; F were 5x more common than M. https://t.co/eqpBmbatSm https://t.co/nq4AFrTAfQ
Links:
Dr. John Cush RheumNow ( View Tweet)
10 yr Spanish study evaluated PET/CT in newly dx inflammatory myositis (except IBM); /77131 IIM pts had PET/CT screening for occult cancer with AUC ROC of 0.87; those not evaluated for OC did not develop cancer after median 3.3 years https://t.co/425o2cEhbJ https://t.co/5EWQzL07he
Links:
Dr. John Cush RheumNow ( View Tweet)
MTX-Sparing in myasthenia gravis. 18-mo OL RCT of MTX vs PBO in 35 recently Dx, pred Rx MG pts (MGFA Class II/III) showed @ 18 mos MTX reduced Pred use (5,663 vs 6,684 mg total), w/ shorter pred reduction times and less daily dose mos 6, 9–18 https://t.co/8t2sJMwBnx https://t.co/3G0wd1FQ2s
Links:
Dr. John Cush RheumNow ( View Tweet)
French study of "Pre-Hab" before Total Knee replacement (prospective, OL, randomized trial) in 262 Knee OA pts >50yrs; saw no benefit of PreHab before TKR. 4 d post surgery, functional independence was same in PreHab (34%) & control (27%) https://t.co/0kXMNEfz4b. https://t.co/yhzk2MyZE3
Links:
Dr. John Cush RheumNow ( View Tweet)
Lit review of MDA5 antibody-positive clinically amyopathic dermatomyositis w/ ILD - shows limited data from 15 studies, 388 pts, 1 RCT: ? best survival with high-dose steroids + immunosuppressive (CTX or CyA/tacrolimus). Refractory dz Rx w/PLEX, Tofa, RTX https://t.co/LIl23O6x2Y https://t.co/qvISwpr7Mw
Links:
Dr. John Cush RheumNow ( View Tweet)
Dr. J Merola discusses the bridges and gaps in PsO/PsA care here in the US. #RNL2022 @RheumNow https://t.co/hIdtRzeUC3
Dr. Rachel Tate uptoTate ( View Tweet)
#ClinicalPearl? Microbiome changes if on vancomycin but not #methotrexate. ? Relevance Dunno #RNL2022 @RheumNow https://t.co/skvu2WGq8w
Janet Pope Janetbirdope ( View Tweet)
Network meta-analysis reviewing PsO biologic treatments and QoL reviewed by Dr. K. Gordon at #RNL2022 @RheumNow https://t.co/BV8s1LJ7VX
Dr. Rachel Tate uptoTate ( View Tweet)
"Going to a dermatologist is like going to a bagel shop, you're gonna get a 'smear'" - Dr. K Gordon #RNL2022 on use of topical corticosteroids as a tool that we should not forget for pts w/#psoriasis https://t.co/vCjMyKe5AE
TheDaoIndex KDAO2011 ( View Tweet)
Such a great and rewarding experience of my first visit to Texas #RNL2022 @RheumNow @UnaMakris https://t.co/fHqX292yzq
Elena MyasoedovaMD MyasoedovaElena ( View Tweet)
Phases preceding RA diagnosis.
@karen_kc123 @RheumNow #RNL2022 https://t.co/KJT9ml8ZJY
Nouf Al hemmadi NoufAhmedAlham2 ( View Tweet)
Completed early RA prevention trial!
One dose of Rituximab at day zero in the PRAIRI Trial, delayed onset of RA diagnosis.
After 36 months mo difference .
@karen_kc123 @RheumNow #RNL2022 https://t.co/R3639V6b07
Nouf Al hemmadi NoufAhmedAlham2 ( View Tweet)
Patient-centered, holistic approach in #multimorbidity management.
🔑 Patients with #RA and #MM need help and coaching in guiding and directing their care.
🔑 Good communication with healthcare provider is the key.
@RheumNow #RNL2022 https://t.co/iLrZAT0y9r
Elena MyasoedovaMD MyasoedovaElena ( View Tweet)
Approaching comorbidities!
Elena Myasoedova @RheumNow #RNL2022 https://t.co/Y3JNsBT9bJ
Nouf Al hemmadi NoufAhmedAlham2 ( View Tweet)
Thanks for coming to RheumNow Live! We'll see you next year! #RNL2022
Dr. John Cush RheumNow ( View Tweet)
"Remember bony growth is a feature of the PsA joint and one potential way in which IL17s may target the disease." Dr. B. Kirkham discusses potential synergistic activity of IL17A and TNFi in the SpA joint. #RNL2022 @RheumNow https://t.co/L9uZqoen2w
Dr. Rachel Tate uptoTate ( View Tweet)
"Instead of using the term moderate to severe PsO, I use systemic treatment eligible PsO," when thinking about medications for PsO patients. Dr. B. Strober. #RNL2022 @RheumNow
Dr. Rachel Tate uptoTate ( View Tweet)